Oncoinvent
Zealand wins in obesity, Genmab hits first-line DLBCL and Oncopeptides crosses the blood-brain barrier – the Nordic Pulse | 2026:41
A quarter of billion-euro licences, a Novo comeback and a flat Nordic index – the State of Nordic BioPharma | 2026:Q3
Analytics
Nanexa lands billion-euro Novo deal, Nordic index slides nearly three per cent – the Nordic Pulse | 2026:39
AstraZeneca’s hat-trick, a broad sell-off and Alzinova funds its Alzheimer’s push – the Nordic Pulse | 2026:37
Demant raises the bar, XVIVO clears hearts and Zealand cashes in – the Nordic Pulse | 2026:33
Leqembi under the skin, Wegovy wins Europe, Sobi lifts guidance – the Nordic Pulse | 2026:29
Alvotech cashes up, SynAct narrowly misses – the Nordic Pulse | 2026:25
Oncoinvent presenterar positiva långtidsdata för Radspherin
Sammanslagningen mellan BerGenBio och Oncoinvent är nu slutförd
Oncoinvent presenterar fas I/IIa-resultat vid PSOGI
Oncoinvent tar nästa steg med Radspherin
Oncoinvent presenterade nyligen slutresultaten från sin fas I-studie...
Bioteknik
Premium
Studieresultat
Oncoinvent rapporterar positiva fas I-resultat för Radspherin
MARKET SIGNAL
ANALYS
Dagens nyhetssvep
Nyhetssvepet fredag 13 november
NYHETSBREV
ANALYTICS
Nine of ten AstraZeneca analyst houses raised their targets after Q3
Sobi: eight analysts, eight raises – but three targets remain below the share price
Egetis attracts a bid and agrees to sell its priority review voucher, Lytix meets its endpoint in melanoma and Novo raises its outlook – the Nordic Pulse | 2026:45
Kommande event
MedTech Summit 2027
After a phenomenal debut last year, the premier gathering for medical technology is officially back. The response to our inaugural...
Global Forum 2027
Global Forum Returns for its 4th Edition. The premier networking event for Nordic life science companies, investors, and industry experts...
Investor Cardiometabolic Day
An exclusive boutique event in Copenhagen dedicated entirely to investors, C-level executives, and key leaders working within the cardiometabolic field....
Rekommenderat
Oncopeptides om EU-godkännandet som flyttar Pepaxti till tredje linjen
Rekordförsäljning för RaySearch men marginalen pressas
Xbrane om FDA-godkännandet som öppnar USA för Lucamzi
Hansa om IND-ansökan för HNSA-5487 och utvalda PAES-resultat
AcuCort ur startblocken – siktar mot USA och svarta siffror
Du är värd det bästa!
Lås upp vårt premium-innehåll: Bli prenumerant!
Skapa konto
